Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy.

Pairwise comparisons confirmed highly significant differences between groups, with the exception of tumors containing isolated CREBBP or EP300 mutations (Dunn’s post hoc test, Mann–Whitney U test).

also in 132,142 other papers